Agenus shared a post on LinkedIn:
“At Agenus, increasing physician-initiated inquiries for authorized access to investigational therapies require thoughtful, disciplined support.
Today, Agenus announced the expansion of our global Medical Affairs infrastructure to support authorized access requests for botensilimab plus balstilimab (BOT+BAL) through existing regulatory pathways, including France’s multi-tumor AAC framework and physician-initiated named-patient programs where permitted.
This expansion reflects growing interest from oncologists worldwide and ensures requests are supported with appropriate scientific engagement, regulatory oversight, and patient safety safeguards.
Read the full release.”
